National Comprehensive Cancer Network® (NCCN®) recommendations
Liposomal daunorubicin and cytarabine (VYXEOS) is the ONLY treatment recommended in the NCCN Clinical Guidelines in Oncology (NCCN Guidelines®) for induction in patients ≥60 years of age with therapy-related AML or antecedent MDS/CMML or AML-MRC (Category 1)1
Liposomal daunorubicin and cytarabine (VYXEOS) is recommended for the following patients1:
≥60 years | Treatment | |
Category 1 recommendation |
Induction therapy |
Therapy-related AML or antecedent MDS/CMML or AML-MRC |
Category 2A recommendation |
Reinduction | Patients with residual disease (preferred only if given in induction)a |
Consolidation | Postremission therapy in patients with complete response (preferred only if given in induction) |
<60 years | Treatment | |
Category 2B recommendation |
Induction therapy |
Therapy-related AML other than CBF/AML or antecedent MDS/CMML or cytogenetic changes consistent with MDS (AML-MRC) |
Category 2A recommendation |
Reinduction | Patients with significant residual disease without a hypocellular bone marrow (preferred only if given in induction; bone marrow aspirate and biopsy 14-21 days after start of therapy)b |
Consolidation | Postremission therapy in treatment-related disease other than CBF and/or unfavorable cytogenetics and/or molecular abnormalities (preferred only if given in induction)c |
≥60 years |
Category 1 recommendation |
Induction therapy: Therapy-related AML or antecedent MDS/CMML or AML-MRC |
Category 2A recommendation |
Reinduction: Patients with residual disease (preferred only if given in induction)a Consolidation: Postremission therapy in patients with complete response (preferred only if given in induction) |
<60 years |
Category 2B recommendation |
Induction therapy: Therapy-related AML other than CBF/AML or antecedent MDS/CMML or cytogenetic changes consistent with MDS (AML-MRC) |
Category 2A recommendation |
Reinduction: Patients with significant residual disease without a hypocellular bone marrow (preferred only if given in induction; bone marrow aspirate and biopsy 14-21 days after start of therapy)b Consolidation: Postremission therapy in treatment-related disease other than CBF and/or unfavorable cytogenetics and/or molecular abnormalities (preferred only if given in induction)c |
- With therapy-related AML or antecedent MDS/CMML or AML-MRC.1
- With therapy-related AML other than CBF-AML/APL or antecedent MDS/CMML or AML-MRC.1
- In patients with therapy-related AML or antecedent MDS/CMML or AML-MRC.1